Dr. Markus Jörger

A small study, presented at ESMO Congress 2018 suggests that the orally administered fibroblast growth factor receptor (FGFR) inhibitor rogaratinib could be beneficial for a subset of patients with head and neck cancer. Dr. Markus Jörger, Kantonsspital St. Gallen, presenting the collective outcome of two combined phase I trials.

Dr. Markus Jörger, Medical oncologist at the Cantonal Hospital in St. Gallen (Switzerland), talks about the importance of tumor agnostics for future cancer drug development.

This is our swiss expert with an overview of sunday's Highlights that will be presented at the presidential symposium.